Biocryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
Holding BCRX?
Track your performance easily

BioCryst (BCRX) Ownership - Who Owns BioCryst?

2,137 Followers

BioCryst (BCRX) Ownership Overview

6.34%17.17%4.38%16.97%55.15%
4.38% Other Institutional Investors
16.97% ETFs
55.15% Public Companies and Individual Investors
The ownership structure of BioCryst (BCRX) stock is a mix of institutional, retail, and individual investors. Approximately 38.51% of the company’s stock is owned by Institutional Investors, 6.34% is owned by Insiders, and 55.15% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Jun 25, 2024
Amy E Mckee
Director
xxxxxxxxxxxxx
$54352
Jun 17, 2024
xxxxxxxxxxxxx
$28134
Jun 14, 2024
xxxxxxxxxxxxx
$40925
May 31, 2024
Alan Levin
Director
xxxxxxxxxxxxx
$49996

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2024
xxxxxxxxxxxxx
$468308
Jun 30, 2024
xxxxxxxxxxxxx
$17654424
Jun 30, 2024
xxxxxxxxxxxxx
$50279268

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
15,698,817Institution7.58%122,136,796
13,678,320Institution6.60%106,417,330
10,406,797Institution5.02%80,964,881
10,204,089Insider4.98%79,387,812
8,135,804Institution3.93%63,296,555
4,491,744Institution2.17%34,945,768
4,360,105Institution2.10%33,921,617
2,856,703Institution1.38%22,225,149
2,314,582Institution1.12%18,007,448
2,156,580Institution1.04%16,778,192

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
13,678,320Institution6.60%106,417,330
4,360,105Institution2.10%33,921,617
2,314,582Institution1.12%18,007,448
2,156,580Institution1.04%16,778,192
1,787,181Institution0.86%13,904,268
1,269,343Institution0.61%9,875,489
1,215,893Institution0.59%9,459,648
1,049,961Institution0.51%8,168,697
1,040,079Institution0.50%8,091,815
788,652Institution0.38%6,135,713

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
6,565,524Institution3.17%49,897,982
5,626,910Institution2.72%43,777,360
4,183,875Institution2.02%32,090,321
3,144,692Institution1.52%23,899,659
2,593,084Institution1.25%19,707,438
1,863,888Institution0.90%14,501,049
1,428,013Institution0.69%10,852,899
1,373,966Institution0.66%10,689,455
1,004,143Institution0.48%7,701,777
947,738Institution0.46%7,202,809

FAQ

Who Owns Biocryst Pharmaceuticals (BCRX)?
According to the latest TipRanks data, approximately 4.38% of the company's stock is held by institutional investors, 6.34% is held by insiders, and 55.15% is held by retail investors.
    What percentage of Biocryst Pharmaceuticals (BCRX) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 4.38% of Biocryst Pharmaceuticals (BCRX) stock is held by institutional investors.
      What percentage of Biocryst Pharmaceuticals (BCRX) stock is held by retail investors?
      According to the latest TipRanks data, approximately 55.15% of Biocryst Pharmaceuticals (BCRX) stock is held by retail investors.
        Who owns the most shares of Biocryst Pharmaceuticals (BCRX)?
        Vanguard owns the most shares of Biocryst Pharmaceuticals (BCRX).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis